GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record sales for Shingrix this year.

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

GSK plc (NYSE:GSK) is one of the most affordable yet financially rewarding healthcare stocks to buy right now, According to Insider Monkey’s database, 41 hedge funds are bullish on the stock ...

The investment community will be closely monitoring the performance of GSK in its forthcoming earnings report. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter.

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...